Highlights MannKind Corporation

Equities

MNKD

US56400P7069

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
4.45 ^USD	-1.11%		+1.14%	+22.25%

May. 08	Transcript : MannKind Corporation, Q1 2024 Earnings Call, May 08, 2024
May. 08	Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (MNKD) MANNKIND Posts Q1 EPS $0.05	May. 08	MT
Earnings Flash (MNKD) MANNKIND Reports Q1 Revenue $66.3M, vs. Street Est of $60.6M	May. 08	MT
MannKind Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial Lung Disease	May. 06	CI
MannKind Corporation to Proceed with Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	Apr. 30	CI
MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment	Apr. 29	MT
MannKind Corporation Announces IND Clearance from U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial Lung Disease	Apr. 29	CI
MannKind Corporation Announces INHALE-3 Study?s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections and Insulin Pumps	Mar. 11	CI
Earnings Flash (MNKD) MANNKIND Reports Q4 Revenue $58.5M, vs. Street Est of $53.1M	Feb. 27	MT
MannKind Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®	Feb. 15	CI
MannKind Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (MNKD) MANNKIND Reports Q3 Revenue $51.3M, vs. Street Est of $50.7M	Nov. 07	MT
MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 Diabetes	Nov. 06	CI
MannKind Reports Q2 Breakeven, Revenue Rises	23-08-08	MT
MannKind Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Earnings Flash (MNKD) MANNKIND Reports Q2 Revenue $48.6M, vs. Street Est of $42.9M	23-08-07	MT
Earnings Flash (MNKD) MANNKIND Reports Q2 EPS $0.00, vs. Street Est of $-0.04	23-08-07	MT
Mannkind Corporation Launches Inhale-3 Study to Address the Most Important Unmet Need in Adults Living with Type 1 Diabetes	23-06-22	CI
MannKind's Q1 Loss Narrows, Revenue Rises	23-05-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MannKind Corporation

Equities

MNKD

US56400P7069

Highlights

Filters